Last reviewed · How we verify
BM2216 Extended-Release tablets(5.5mg) — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
BM2216 Extended-Release tablets(5.5mg) (BM2216 Extended-Release tablets(5.5mg)) — Zhejiang Anglikang Pharmaceutical Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| BM2216 Extended-Release tablets(5.5mg) TARGET | BM2216 Extended-Release tablets(5.5mg) | Zhejiang Anglikang Pharmaceutical Co., Ltd. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- BM2216 Extended-Release tablets(5.5mg) CI watch — RSS
- BM2216 Extended-Release tablets(5.5mg) CI watch — Atom
- BM2216 Extended-Release tablets(5.5mg) CI watch — JSON
- BM2216 Extended-Release tablets(5.5mg) alone — RSS
Cite this brief
Drug Landscape (2026). BM2216 Extended-Release tablets(5.5mg) — Competitive Intelligence Brief. https://druglandscape.com/ci/bm2216-extended-release-tablets-5-5mg. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab